NGM - NGM Biopharmaceuticals, Inc.
| Previous Close | 14.11 |
| Open | 14.13 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 1400 |
| Day's Range | 13.92 - 14.27 |
| 52 Week Range | 12.00 - 18.75 |
| Volume | 28,377 |
| Avg. Volume | 86,120 |
| Market Cap | 926.287M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.74 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.50 |
- GuruFocus.com•22 hours ago
Weekly Top Insider Buys Highlight for the Week of July 19
The largest Insider Buys this week were for Fastenal Co., HealthEquity Inc., Hyster-Yale Materials Handling Inc. and NGM Biopharmaceuticals Inc. Continue reading...
- Simply Wall St.•11 days ago
How Much Are NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Insiders Spending On Buying Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
- GlobeNewswire•last month
NGM Bio to Present at Goldman Sachs 40th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 10, 2019 -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative.
- GlobeNewswire•2 months ago
NGM Bio to Present New Data from Phase 1b Study of NGM313 at 79th Scientific Sessions of the American Diabetes Association
SOUTH SAN FRANCISCO, Calif., June 05, 2019 -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative.
- GlobeNewswire•3 months ago
NGM Bio Announces Multiple Presentations at The International Liver Congress™ 2019
SOUTH SAN FRANCISCO, Calif., April 08, 2019 -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on harnessing powerful biology to.
- American City Business Journals•4 months ago
The Funded: 10 Bay Area startups disclose over $175M in funding at week's end
Another unicorn is lining up an IPO for later this year and 10 Bay Area companies raised about $175 million in funding at week's end. Here are the details.
- GlobeNewswire•4 months ago
NGM Bio Announces Pricing of Initial Public Offering
NGM Biopharmaceuticals, Inc. (“NGM”) today announced the pricing of its initial public offering of 6,666,667 shares of common stock at a price to the public of $16.00 per share. In addition, NGM has granted the underwriters a 30-day option to purchase up to 1,000,000 additional shares of common stock at the initial public offering price less underwriting discounts and commissions. The shares are expected to begin trading on The Nasdaq Global Select Market under the symbol “NGM” on April 4, 2019, and the offering is expected to close on April 8, 2019, subject to customary closing conditions.
- Benzinga•4 months ago
IPO Outlook For The Week: Ruhnn, Silk Road Medical, NGM Biopharmaceuticals And A Trading Platform
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. Ruhnn Holding Ltd (RUHN) will issue 10 million shares between $11.50 ...
- MoneyShow•4 months ago
TPI Composites- Blowing in the Wind
TPI Composites (NGM) makes wind blades for wind turbines which it sells to turbine manufacturers; in fact it is the only independent manufacturer of composite wind blades for the high growth wind energy market with a global footprint, explains small cap expert Tom Bishop, editor of BI Research.
